SELLAS Life Sciences Group Inc

NASDAQ:SLS   3:20:30 PM EDT
2.35
+0.02 (+0.86%)
Products, Regulatory

Sellas Life Sciences Announces Update On Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, In Acute Myeloid Leukemia

Published: 11/14/2022 13:10 GMT
SELLAS Life Sciences Group Inc (SLS) - Sellas Life Sciences Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-s, in Acute Myeloid Leukemia.
Sellas Life Sciences Group Inc - 3d Medicines to Participate in Regal Clinical Trial, Which Will Trigger Significant Milestone Payments to Sellas.
Sellas Life Sciences Group Inc - Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan.
Sellas Life Sciences Group Inc - Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events in Regal Clinical Trial.